drugset / Trial / NCT04876937

Low-Dose Dexmedetomidine for Delirium Prevention in Mechanically Ventilated Septic Patients

NCT04876937 ↗

RandomizedParallel-groupQuadruple-blindPrevention

Summary

Delirium is common in septic patients, especially those receiving mechanical ventilation in the intensive care unit (ICU). Dexmedetomidine is a highly selective α2 adrenoreceptor agonist with anxiolytic, sedative, analgesic, and anti-inflammatory effects. Use of dexmedetomidine in mechanically ventilated ICU patients is associated with less delirium and improved outcomes. However, dexmedetomidine infusion produces dose-dependent bradycardia and hypotension; these limited the use of dexmedetomidine in ICU patients. This study is designed to test the hypothesis that low-dose dexmedetomidine infusion can also reduce delirium in mechanically ventilated ICU patients with sepsis.

Timeline

Start
2021-05-28
Primary completion
2024-02-02
Completion
2024-03-02

Outcome

Outcome not reported

Stopped (Enrollment): “The trial was stopped prematurely because of slow recruitment.”

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Dexmedetomidine Other / unclassified 0.1 ug/kg Other
Subject Dexmedetomidine Other / unclassified 0.2 ug/kg Other